Natco Pharma Board of Directors
Get the latest insights into the leadership at Natco Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Chekuri Venkat Ramesh | Company Secretary & Compliance Officer |
| V C Nannapaneni | Chairman & Managing Director |
| Rajeev Nannapaneni | Vice Chairman & CEO |
| PSRK Prasad | Executive Director & Executive Vice President (Corporate Engineering Services) |
| D Linga Rao | Executive Director & President (Technical Affairs) |
| ADM Chavali | Non Executive Independent Director |
| Dronadula Vijaya Bhaskar | Non Executive Independent Director |
| Kantipudi Suma | Non Executive Independent Director |
| Nitin Jain | Non Executive Independent Director |
| Lakshminarayana Bolisetty | Non Executive Independent Director |
Natco Pharma FAQs
The board at Natco Pharma consists of experienced professionals, including Chekuri Venkat Ramesh, V C Nannapaneni, and others, overseeing the company’s strategic and corporate governance.
Directors at Natco Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Chekuri Venkat Ramesh is the current chairman at Natco Pharma.
Executive directors at Natco Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Natco Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Natco Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
